Yunxiao Zhang

Yunxiao Zhang

Auto-generated profile, based on publicly available information

Yunxiao Zhang

Key Laboratory of Hunan Province for Advanced Carbon-based Functional Materials, School of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang, Hunan 414006, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Catalysis
Verified
Journal Article
Closed access
QCQingxiang Cao
Qingxiang Cao
XWXuelian Wu
Xuelian Wu
YZYunxiao Zhang
Yunxiao Zhang
BYBo Yang
Bo Yang
XMXIAOFEN MA
XIAOFEN MA
JZJunmin Zhang
Junmin Zhang

23 March 2024 in Protein Expression and Purification
Verified
Journal Article
Closed access
DPDezheng Peng
Dezheng Peng
YLYang Li
Yang Li
LSLinlin Si
Linlin Si
BZBo Zhu
Bo Zhu
PWPeng Wu
Peng Wu
YZYunxiao Zhang
Yunxiao Zhang

16 August 2024 in Journal of Materials Science
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
SHShanxia Hu
Shanxia Hu
THTiantian Hu
Tiantian Hu
JZJingqiang Zhang
Jingqiang Zhang
MWMengting Wang
Mengting Wang
YZYunxiao Zhang
Yunxiao Zhang

9 September 2024 in Advanced Science
Verified
Journal Article
Open access
SLSen Luo
Sen Luo
XZXi Zhou
Xi Zhou
MWMeijing Wu
Meijing Wu
GWGongxin Wang
Gongxin Wang
LWLi Wang
Li Wang
ZLZhonghua Liu
Zhonghua Liu
The inhibition of Nav1.7 is a promising strategy for the development of analgesic treatments. Spider venom‐derived peptide toxins are recognized as significant sources of Nav1.7 inhibitors. However, their development has been impeded by limited selectivity. In this study, eight peptide toxins from three distinct spider venom Nav channel families demonstrated robust inhibition of hNav1.7, rKv4.2, and rKv4.3 (rKv4.2/4.3) currents, exhibiting a similar mode of action. The analysis of structure and function relationship revealed a significant overlap in the pharmacophore responsible for inhibiting hNav1.7 and rKv4.2 by HNTX‐III, although Lys25 seems to play a more pivotal role in the inhibition of rKv4.2/4.3. Pharmacophore‐guided rational design is employed for the development of an mGpTx1 analogue, mGpTx1‐SA, which retains its inhibition of hNav1.7 while significantly reducing its inhibition of rKv4.2/4.3 and eliminating cardiotoxicity. Moreover, mGpTx1‐SA demonstrates potent analgesic effects in both inflammatory and neuropathic pain models, accompanied by an improved in vivo safety profile. The results suggest that off‐target inhibition of rKv4.2/4.3 by specific spider peptide toxins targeting hNav1.7 may arise from a conserved binding motif. This insight promises to facilitate the design of hNav1.7‐specific analgesics, aimed at minimizing rKv4.2/4.3 inhibition and associated toxicity, thereby enhancing their suitability for therapeutic applications.

28 April 2023 in Journal of Materials Science
Verified
Journal Article
Closed access
PDF file
YZYunxiao Zhang
Yunxiao Zhang
WXWenhua Xiao
Wenhua Xiao
THTiantian Hu
Tiantian Hu
SHShanxia Hu
Shanxia Hu
HWHongqiang Wang
Hongqiang Wang
BHBinhong He
Binhong He

1 December 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MCMinzhi Chen
Minzhi Chen
SPShuijiao Peng
Shuijiao Peng
LWLi Wang
Li Wang
LYLi Yang
Li Yang
YSYuxin Si
Yuxin Si
ZLZhonghua Liu
Zhonghua Liu